Objective To explore the clin. efficacy of Tripterygium Wilfordii Polyglycoside Tablets combined with natrium-glucose cotransporter 2 inhibitors in the treatment of diabetic nephropathy.Methods This study included 102 patients with diabetic nephropathy.By the random number table method, 102 patients were divided into observation group and control group, with 51 cases in each group.The control group (51 cases) was given natrium-glucose cotransporter 2 inhibitors (Dapagilflozin Tablets-Forxiga).The observation group (51 cases) used Tripterygium Wilfordii Glycosides Tabletscombinedwith natrium-glucose cotransporter 2 inhibitors.The clin. efficacy, changes of renal function, changes of serum inflammatory factors, changes of proteinuria and serum immune factors, changes of symptom scores, adverse drug reactions in the treatment process and patients′ satisfaction with the treatment were compared between the two groups.Results Compared with the control group 60.78% (31/51), the observation grouphad a higher total effective rate 80.39% (41/51) after clin. treatment (P<0.05).Beforetreatment, two groups′ blood urea nitrogen (BUN), serum creatinine (Scr), renal function indexes such ashypersensitive C-reactive protein (hs-CRP) and inflammatory cytokinesinterleukin 6 (IL-6) and interleukin 8 (IL-8) and serum levels of 24 h proteinuria quant., IgA (IgA), IgG (IgG), C3 and C4 and symptom integral werenot significant (P>0.05).After treatment, BUN, Scr, hs-CRP, IL-6, IL-8, 24 h proteinuria, IgA, IgG, C3, C4, symptom score and other indicators were all improved to a certain extent in each group.And those in the observation group were better than those in the control group (P<0.05).Adverse reaction incidence in the observation group was 1.96% (1/51), which was equivalent to 3.92% (2/51) in the control group (P>0.05).The satisfaction rate of patients in the observation group 98.04% (50/51) was significantly higher than that in the control group (84.31%) (P<0.05).Conclusion Tripterygium Wilfordii Polyglycoside Tablets combined with natrium-glucose cotransporter 2 inhibitor have significant clin. efficacy in the treatment of diabetic nephropathy patients.It can significantly improve liver and kidney function, relive the symptoms, improve immunity, and have fewer adverse reactions as well as high safety, and patients are very satisfied, worthy of clin. promotion and application.